12,372 trials
Infections, Papillomavirus
Primary: Number of Subjects With HPV DNA in Cervical Samples by Hybrid Capture 2 Test (HCII) — 615; 828; 24; 418 Participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481
Complicated Intra-abdominal Infection
Primary: The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 83.0; 87.3 percentage…
Complicated Urinary Tract Infection · Pyelonephritis
Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…
Ovarian Neoplasms · Peritoneal Neoplasms
Primary: PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria. — 17.2…
Pain
Primary: The Number of Participants With Adverse Events as a Measure of Safety. — 3; 2; 8; 8 participants
Tinnitus
Primary: Tinnitus Distress Rating — 5.71; 5.82; 5.36; 5.46 units on a scale
Allergic Rhinitis
Primary: Scores on a Scale (Average of Daily Rhinoconjunctivitis Symptom Score (RSS) Recorded During the Ragweed Season — 6.2; 6.5 Scores on a scale — p=<0.05
Cervical Cancers · Vulvar Cancer · Vaginal Cancer
Primary: Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])…
Pulmonary Arterial Hypertension
Primary: Change in Pulmonary Vascular Resistance From Baseline to End of Treatment (EOT). — 595.70; 587.66 dyn/sec/cm^5
Human Papillomavirus Infection
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 2198.7; 2260.7; 1495.0; 1547.2 milli Merck…
Childhood Acute Basophilic Leukemia · Childhood Acute Eosinophilic Leukemia · Childhood Acute Erythroleukemia (M6)
Primary: Event-free Survival (EFS) at 3 Years — 90.1 percentage
Parkinson's Disease
Primary: Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)…
Leukemia
Primary: Event-free Survival at 3 Years — 46.9; 53.1; 50.0 percentage of participants
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With Persisting Serum Bactericidal Titers ≥1:5 and ≥1:8 (at 4 Years of Age), Who Had Previously Received Three Primary Doses and One Booster Dose…